Pre-Funded Warrants (October 2026 PIPE)
Issued 2026
Shares Underlying
Exercise Price
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 28 of Atrium Therapeutics, Inc.'s SEC filings and found 1 warrant series and 1 completed offering on file for RNA. The latest dilution event on file is an offering on Oct 9, 2026. Analysis updated Nov 14, 2026.
Raise routes on file: no active ATM, effective shelf, issuer S-1 or active equity line in the filings read · latest dilution event 38 days ago
The dominant contractual driver and its mechanism, then each further driver ranked.
Oct 9, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)
Shares outstanding, potential dilution and cash over time
Issued 2026
Shares Underlying
Exercise Price
Issued 2026
Gross proceeds
Price per share
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)
DilutionScanEvery instrument in full · From $29.99/mo
Covered companies in Biotechnology. All tickers A to Z